All News
Filter News
Found 806,088 articles
-
Verve Therapeutics CEO Sekar Kathiresan, M.D., to Give Keynote Presentation at the International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting
6/17/2020
Verve Therapeutics , a next-generation cardiovascular company developing medicines that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics, will give a keynote presentation on the genetic basis for risk and resistance to coronary heart disease and gene editing as a p
-
Sanofi announced plans to increase its vaccines research and production capabilities. As part of the plan it will invest $679.4 million (€610 million) to create a new production site and a research center, both in France.
-
The game was reviewed through the agency’s de novo pathway and as a result, creates a new class of digital therapeutics.
-
Neurocrine Biosciences is partnering with Japan’s Takeda Pharmaceutical to develop and commercialize molecules in Takeda’s early-to-mid-stage psychiatry pipeline.
-
The two companies will explore potential oncology treatments with emerging technology.
-
The approval was based on monotherapy clinical data from a trial in 105 adults with SCLC whose disease progressed after platinum-based chemotherapy.
-
Dexamethasone Reduces Deaths in Hospitalized COVID-19 Patients Needing Oxygen, Study Shows
6/16/2020
Low doses of a long-used steroid known as dexamethasone could be the solution to improving the chances of patients who become seriously ill from COVID-19 infection and require some kind of breathing assistance. -
The warning came only a few hours after the FDA rescinded Emergency Use Authorization (EUA) for hydroxychloroquine and chloroquine for the treatment of COVID-19.
-
Before the end of this year, 4DMT intends to launch clinical trials for 4D-310, its product candidate for the treatment of Fabry disease, and 4D-125 and 4D-110, its two ophthalmology product candidates.
-
In a Phase III study, Eli Lilly’s Verzenio combined with standard adjuvant endocrine therapy met its primary endpoint of invasive disease-free survival in high-risk breast cancer and significantly reduced the risk of a recurrence of the disease.
-
Data presented at the virtual American Diabetes Association meeting has Pfizer excited about the promise of its GLP-1R Agonist PF-06882961.
-
Of the resumes submitted to employers that use Applicant Tracking Systems (ATS), 75% are never seen by human eyes.
-
Magellan Health Appoints Dr. Caroline Carney as Chief Medical Officer
6/16/2020
Magellan Health, Inc. (NASDAQ: MGLN) today announced it has appointed Caroline Carney, MD, MSc, FAPM, CPHQ, as chief medical officer of Magellan Health.
-
UM School of Medicine Researchers Receive Federal Funding to Rapidly Test New Treatments for COVID-19
6/16/2020
Long-time Coronavirus Researcher Joins Collaboration to Rapidly Repurpose FDA-approved Drugs for COVID-19
-
Black Diamond Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
6/16/2020
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s business at the BMO 2020 Prescriptions for Success Healthcare Conference.
-
Osmotica Pharmaceuticals plc to Present at Jefferies Virtual Optical Health Summit
6/16/2020
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at the Jefferies Virtual Optical Health Summit
-
Inozyme Pharma Announces Changes to Its Board of Directors
6/16/2020
Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today the appointment of Doug Treco, Ph.D., as Chairman of the Company’s Board of Directors
-
Flexion Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
6/16/2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference.
-
Cascade Chemistry Selected to Produce Active Pharmaceutical Ingredient for Clinical Trial Supplies of COVID-19 Investigational Drug RBT-9
6/16/2020
Cascade Chemistry, a leading contract research and manufacturing organization serving the pharmaceutical, materials, and chemical industries, today announced that it has been selected to produce the active pharmaceutical ingredient (API) for clinical trial supplies of RBT-9, an investigational therapy entering a Phase 2 trial for the treatment of COVID-19 patients who are at high risk of deteriorating health due to age or comorbid conditions such as kidney or cardiovascular disease.
-
NGMedical GmbH Establishes a Delaware Corporation and Moves Toward Commercialization in the United States
6/16/2020
NGMedical, a German medical device manufacturer exclusively focused on creating innovative technologies for spinal application announces major milestones in preparation of its anticipated 510(k) approval later in 2020.